This two-day course will teach the different methods of wound debridement, with a special focus on conservative sharp debridement, facilitated by the Newcastle Hospitals’ Tissue Viability Team with guest speaker specialists from Dermatology, Plastics, Podiatry as well as a physiology and anatomical expert.
This course explains why breast cancer arises, the different ways that the DNA in our cells gets damaged and the targeted treatments that match a few of the known mutations. It also explores the science behind hormone therapies, targeted therapies, and immunotherapies given to patients with hormone receptor-positive, HER2-positive, and triple-negative breast cancer.
A unique Specialist Consultant taught interactive educational experience for the referring and reporting of Cone Beam CT. Validated by the Royal College of Physicians and Surgeons (Glasgow) in order to match the recommended hours for Level 2 reporting.
Our Laser Protection Supervisor (LPS) Training encompasses the fundamental principles of laser safety. We combine self-paced learning materials with practical scenario-based teaching. This course aims to provide you with the appropriate knowledge and confidence to fulfil your duties as an LPS in your workplace.
Haematological cancers differ from solid tumours in many ways: in the mutations that drive them, their interactions with their environment, and the treatments that are effective against them. This course introduces the biology, behaviours and genetics of this diverse group of diseases with a focus on the features we can now target and the mechanisms of action of the various treatments
During this introduction to the science behind a wide variety of systemic treatments given to people with prostate, bladder, or kidney cancer, Dr Elaine Vickers will discuss current hormone therapies, immunotherapy and targeted treatments.
A focus on modern systemic treatments for non-small cell lung cancer (NSCLC) as well as the gene faults that drive many NSCLCs; the targeted treatments that exploit these faults, such as inhibitors of EGFR, ALK, ROS1, B-Raf, HER2, MET, and RET; the immune system and checkpoint inhibitor group of immunotherapies, including PD-1, PD-L1 and CTLA-4 targeted antibody therapies